Mizuho maintains neutral on Revance, price target steady at $3.65
Mizuho (NYSE:MFG) analysts maintained a Neutral rating on Revance Therapeutics (NASDAQ:RVNC), a $382 million market cap company, with a steady price target of $3.65. The firm's stance came in the wake ...
Geneos Wealth Management Inc. Has $253,000 Holdings in The Clorox Company (NYSE:CLX)
Geneos Wealth Management Inc. lessened its holdings in shares of The Clorox Company (NYSE:CLX – Free Report) by 8.3% during ...
Morningstar2d
Mizuho Financial Group Inc ADR MFG
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Mizuho raises Sage Therapeutics target to $9 on Biogen bid
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...
MarketWatch17d
Investors have 'a false sense of security' around 5% peak Treasury yields, says Mizuho
Yet "the bond market has not taken on board" the potential for 3% inflation in 2025, Steven Ricchiuto, chief economist at Mizuho Securities, wrote in a Monday client note. Even before December's ...
Seeking Alpha6d
Qorvo in focus as Mizuho ups estimates on activist involvement
Qorvo (NASDAQ:QRVO) shares fell 0.5% in premarket trading on Friday, even as Mizuho Securities upped its earnings estimates on the involvement of activist investor Starboard Value. Mizuho analyst ...
Yahoo Finance12d
Mizuho Financial Group, Inc. (MFG)
This year’s winners from Mizuho Americas were: Serena Lin, Managing Director and Head of Agency Mortgage-Backed Securities Trading Desk for Excellence in Fix NEW YORK, Aug. 28, 2024 (GLOBE ...